reports
Tevogen Bio Files Registration Statement for Previously Disclosed Secu...
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.Includes issuance of shares underlying warrants originally issued in 2021, earnout shares previously registered on recent Registration Statement on Form S-4, and the resale of shares that are outstanding or issuable under previously disclosed securities. WARREN, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or ...
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial R...
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy by the journal . Key Observations: Interventional arm patients...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future ...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of Mittul Mehta, Tevogen’s Chief Information Officer and Head of Tevogen.AI, at the Longwood Spring MIT Conference. Mehta emphasized the transformative potential of Tevogen Bio’s innovative T...
- Sid Rajeev
Fast Tracking a Potential Breakthrough for Treating Viral Infections a...
Tevogen Bio Holdings (TVGN) is a new public biotech company developing off-the-shelf therapies for viral infections, cancers and neurological diseases. Their approach uses the body's natural defenses (CTLs) to target infected or cancerous cells. This could be a more cost-effective and faster treatment than current options. They have promising early results for treating COVID-19 in vulnerable patients and are developing treatments for other diseases as well. The company is early stage and has a ...
Tevogen Bio Set to Join Russell 3000® Index
Tevogen Bio Set to Join Russell 3000® Index WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstituti...
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing t...
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million i...
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Respon...
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday, June 6th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN). Please note that the second paragraph has been corrected and a photo is now included. The corrected release follows: (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), is a clinical-stage specialty immunotherapy compa...
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected...
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressin...
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational...
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long C...
Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Reports First Quarter 2024 Financial Results Confirms liability elimination of $94.9 million and discloses $11.3 million of net incomeReports net cash used for operating activities was $2.1 millionReiterates commitment to both patients and shareholders WARREN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ended March 31, 2024,...
Tevogen Bio Appoints Former Police Chief & FBI National Academy Gradua...
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announces the appointment of William Keane as Vice President of Strategic Initiatives. Mr. Keane brings 35 years of leadership experience in law enforcement, having most recently served as the Chief of Police ...
Tevogen Bio Announces Up to $50 Million in Financing to Further Advanc...
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a binding term sheet [with an existing investor] to secure up to $50 mi...
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Op...
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform for additional clinical trials based on successful completion of POCHighlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virolo...
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liabi...
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding shares.The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access. WARREN, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ) is a clin...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cyt...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma. WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- (Tevogen) (: ), is a clinical-stage specialty immunotherapy biotech ...
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Co...
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- (‘Tevogen Bio’) (Nasdaq: ), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio. Most recently, Mr. Shah was Director, Relationship Management, in Citigroup’s Client organization, where he was also a memb...
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conve...
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- ('Tevogen Bio') (: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, f...
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell The...
WARREN, N.J.--(BUSINESS WIRE)-- ('Tevogen Bio') (: ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences. TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides. TVGN 489’s peptide targets have been preserved in all previously studied COVID strains. Continuing surveillance by Tev...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.